Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 13/20 | 0.45 |
| ▸ | CYP21A2 | P08686 | 12/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP7A1 | P22680 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6895595 | 0.99 | CYP17A1 (0.45) | CYP17A1CYP21A2CYP11B1CYP19A1LSS | |
| Hydrochloric Acid SCHEMBL6891758 | 0.86 | CYP19A1 (0.43) | CYP17A1CYP21A2CYP11B1CYP19A1 | |
| Hydrochloric Acid SCHEMBL6891778 | 0.86 | CYP19A1 (0.43) | CYP17A1CYP21A2CYP11B1CYP19A1 | |
| Hydrochloric Acid SCHEMBL6888286 | 0.84 | THRB (0.43) | LSSCYP3A4 | |
| Hydrochloric Acid SCHEMBL6896902 | 0.83 | CYP19A1 (0.42) | CYP17A1CYP21A2CYP11B1CYP19A1 | |
| SCHEMBL6887379 | 0.83 | LSS (0.45) | LSSCYP3A4 | |
| Hydrochloric Acid SCHEMBL6893853 | 0.82 | LSS (0.45) | LSSCYP3A4 | |
| SCHEMBL6896865 | 0.81 | LSS (0.50) | LSSCYP3A4 | |
| SCHEMBL6895390 | 0.81 | TP53 (0.43) | CYP19A1 | |
| SCHEMBL6895530 | 0.81 | LSS (0.44) | CYP17A1CYP21A2CYP11B1CYP19A1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | CYP17A1 575/4885CYP21A2 205/4885CYP11B1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.